Degradation by Degronimid

C4 Therapeutics Inc. has found a way to harness the ubiquitin-proteasome pathway for targeted protein degradation. The company's Degronimid platform uses small molecules to tether disease-associated proteins to ubiquitin, triggering their degradation by the proteasome.

The company initially plans to use the platform to develop alternatives to traditional inhibitors that could require less frequent or lower doses. "With a traditional inhibitor, you have to maintain drug occupancy because the drug only works when it binds to its target, but a Degronimid only has to bind long enough to induce degradation," said co-founder Nathanael Gray. ...